<DOC>
	<DOCNO>NCT02848170</DOCNO>
	<brief_summary>Phase 3 study examine relation antihypertensive effect baseline factor exploratively , compare olmesartan medoxomil patient essential hypertension .</brief_summary>
	<brief_title>Study CS-3150 Compared Olmesartan Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>Male female subject age 20 year old informed consent Subjects essential hypertension runin period ( mean 24hr systolic blood pressure SBP ≥ 130 diastolic blood pressure DBP ≥ 80 mmHg Sitting SBP ≥ 140 mmHg &lt; 180 mmHg , Sitting DBP ≥ 90 mmHg &lt; 110 mmHg ) Secondary hypertension malignant hypertension Diabetes mellitus albuminuria Serum potassium level &lt; 3.5 ≥ 5.1 mEq/L Reversed daynight life cycle include overnight worker eGFR &lt; 60 mL/min/1.73 m^2 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>essential hypertension</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
</DOC>